Dartmouth-Hitchcock Medical Center

Open enrollment with an early-phase pipeline tilt

According to ClinicalTrials.gov-derived indexes, Dartmouth-Hitchcock Medical Center sits in the top decile of US sponsors by registered trial count (#85 of 15,742 sponsors by registered trial count).

427 total trials 52 currently recruiting 300 completed early-phase tilt top decile by trial count

Dartmouth-Hitchcock Medical Center: 427 sponsored US clinical trials, 52 recruiting.

Dartmouth-Hitchcock Medical Center sponsors 427 registered US clinical trials on ClinicalTrials.gov, 52 of them currently recruiting, and 300 completed. 25 of these trials are in Phase 3-4 (later-stage) and 84 in Phase 1-2 (earlier-stage). The most-studied condition in this pipeline is Breast Cancer, with 12 trials.

Top-decile sponsor footprint

Dartmouth-Hitchcock Medical Center ranks in the top decile of sponsors by registered trial count (#85 of 15,742 sponsors by registered trial count). Volume at this scale usually reflects a long institutional pipeline, read phase tilt and therapeutic areas below before treating it as current-year activity.

Trial completion reliability score

D 53/100

300 of 352 decided trials (Completed vs. Terminated on ClinicalTrials.gov) reached their planned completion (85.2%), vs. national p10 68.4% / p90 100% among 1,234 sponsors with at least 10 decided trials. Still-open trials (Recruiting, Active-not-recruiting, Not-yet-recruiting) are excluded since they have not reached an outcome yet.

Open and recent trials

427 total, page 9 of 9

COMPLETED Phase 4

Treatment for Depression in the Primary Care Setting

NCT00055328

COMPLETED

Redesigning Cardiac Surgery to Reduce Neurologic Injury

NCT00432536

COMPLETED NA

Family Intervention for Mental Illness and Substance Abuse

NCT00043693

COMPLETED Phase 2

Thalidomide and Irinotecan in Treating Patients With Glioblastoma Multiforme Who Have Undergone Radiation Therapy

NCT00039468

COMPLETED NA

Treatment of Post Traumatic Stress Disorder in Patients With Other Mental Illnesses

NCT00053690

COMPLETED Phase 2

A Telephone-Based Prevention Care Manager in Increasing Screening Rates for Breast Cancer, Cervical Cancer, and Colorectal Cancer in Minority and Low-Income Women

NCT00376909

COMPLETED NA

Brief Integrative Therapy for Post-Traumatic Stress Disorder

NCT00047684

COMPLETED NA

Health Care Management and Rehabilitation Skills Training for Treating Serious Mental Illness in Older People

NCT00169052

TERMINATED Phase 1

A Study of Paclitaxel and Carboplatin in Combination With Bexarotene Oral Capsules in Patients With Advanced Lung Cancer

NCT00153842

COMPLETED Phase 1

Temozolomide Plus PEG-Interferon Alfa-2B in Treating Patients With Advanced Solid Tumors

NCT00014261

COMPLETED Phase 4

Treatment of Schizophrenia and Comorbid Cannabis Use Disorder: Comparing Clozapine to Treatment-as-Usual

NCT00498550

COMPLETED Phase 1

Adenosine Triphosphate in Treating Patients With Advanced Solid Tumors

NCT00014248

TERMINATED Phase 1

Antibody Therapy in Treating Patients With Refractory or Relapsed Non-Hodgkin's Lymphoma or Chronic Lymphocytic Leukemia

NCT00014560

COMPLETED Phase 1

Combination Chemotherapy Plus Filgrastim in Treating Patients With Advanced Solid Tumors

NCT00014456

COMPLETED Phase 4

Spine Patient Outcomes Research Trial (SPORT) - Intervertebral Disc Herniation

NCT00000410

COMPLETED Phase 4

Spine Patient Outcomes Research Trial (SPORT): Degenerative Spondylolisthesis With Spinal Stenosis

NCT00000409

COMPLETED Phase 4

Spine Patient Outcomes Research Trial (SPORT): Spinal Stenosis

NCT00000411

COMPLETED Phase 1

Docetaxel and Carboplatin Followed by Oral Capecitabine, Docetaxel and Radiation for Esophageal Cancer

NCT00153881

TERMINATED Phase 2

Temozolomide in Treating Patients With Leptomeningeal Metastases From a Solid Tumor or Lymphoma

NCT00005812

COMPLETED Phase 1

Chemotherapy Plus Trastuzumab in Treating Patients With Breast Cancer

NCT00014430

TERMINATED Phase 4

Alcoholism and Schizophrenia: Effects of Clozapine

NCT00169026

TERMINATED Phase 1

Lepirudin in Treating Patients With Recurrent or Advanced Small Cell Lung Cancer

NCT00003726

COMPLETED NA

Radiation Therapy After Surgery in Treating Women With Phyllodes Tumor of the Breast

NCT00003404

COMPLETED Phase 1

Bispecific Antibody Plus White Blood Cells in Treating Patients With Recurrent or Refractory Glioblastoma Multiforme

NCT00005813

COMPLETED Phase 1

Mitomycin and Mitoxantrone in Treating Patients With Acute Myelogenous Leukemia

NCT00003003

COMPLETED Phase 2

Combination Chemotherapy for Patients With Brain Cancer

NCT00002814

COMPLETED Phase 2

Aspirin/Folate Prevention of Large Bowel Polyps

NCT00272324

← Previous Page 9 of 9

Phase Distribution

PhaseTrial count
Phase 1 44
Phase 2 40
Phase 3 6
Phase 4 19

What is open in the Dartmouth-Hitchcock Medical Center pipeline

52 recruiting of 427 indexed (12% open); 300 completed (70%).

Phase mix: 25 late (III/IV) vs 84 early (I/II) (early-phase heavy).

Top condition: Breast Cancer (12 trials), 9 others listed.

How open-pipeline share is computed

Recruiting share is recruiting_count divided by trial_count for this sponsor in the public registry export. Status can change between pulls; treat the figure as a research-attention snapshot, not product availability.

Dartmouth-Hitchcock Medical Center: open-pipeline peers nationwide

Peers matched on 427 registered trials and 12% open enrollment, not the therapeutic-area sidebar.

Dartmouth-Hitchcock Medical Center sits at or above the median trial volume and at or above the median recruiting share among these 9 nationwide peers -- the two do not always move together. Source: ClinicalTrials.gov (2026-08-08 snapshot). 2×2 strategic matrix plotting 9 entities by Total trials (X) and Recruiting share (Y), with a crosshair dividing the plot into four quadrants. Higher volume & more openFocused & more openHigher volume, mostly closedSmaller & mostly closed 0100200300400500 0%10%20%30% Total trials Recruiting share Dartmouth-Hitchcock Medical CenterUniversity of Illinois at ChicagoVanderbilt UniversityChildren's Hospital of PhiladelphiaNovo Nordisk A/SFriends Research InstituteAntonios LikourezosOregon State UniversityUniversity of Massachusetts, Amherst
Dartmouth-Hitchcock Medical Center sits at or above the median trial volume and at or above the median recruiting share among these 9 nationwide peers -- the two do not always move together. Source: ClinicalTrials.gov (2026-08-08 snapshot).

Dartmouth-Hitchcock Medical Center sits at or above the median trial volume and at or above the median recruiting share among these 9 nationwide peers -- the two do not always move together.

Sponsors near 427 trials (± recruiting share)

Sponsors near 12% open enrollment (± trial volume)

What to do with this Dartmouth-Hitchcock Medical Center page

427 registered trials is a research-attention snapshot, not an endorsement of Dartmouth-Hitchcock Medical Center or any single study.

  • 52 of Dartmouth-Hitchcock Medical Center's trials are currently recruiting, check each one's own eligibility criteria before contacting a site. Browse recruiting trials
  • Breast Cancer is the condition Dartmouth-Hitchcock Medical Center studies most, compare against other sponsors active in the same condition before evaluating a specific study. See Breast Cancer trials
  • Bring the specific trial ID (NCT number) to your own doctor before enrolling, this page is a directory, not medical guidance. Read the trial-finding guide

Trial and recruiting counts reflect ClinicalTrials.gov registry status as of the data vintage above; individual trial eligibility and enrollment status can change.

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. Dartmouth-Hitchcock Medical Center pipeline card: 427 registered trials from official public datasets. See our editorial standards & corrections policy, the methodology behind these numbers, the data changelog, or report a data error.